The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients

References

• Alcalay M, Zangrilli D, Pandolfi PP, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA. 1991;88(5):1977–1981.
   PubMed Web of Science ®Google Scholar
• Alimoghaddam K. A review of arsenic trioxide and acute promyelocytic leukemia. Int J Hematol Oncol Stem Cell Res. 2014;8(3):44–54.
   PubMedGoogle Scholar
• Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health Syst Pharm. 2009;66(21):1913–1918.
   PubMed Web of Science ®Google Scholar
• Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study C9710. Blood. 2010;116(19):3751–3757.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111–121.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295–1305. 2015/10/01/
   PubMed Web of Science ®Google Scholar
• Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630–1643.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer J. 2015;5(4):e304.
   PubMedGoogle Scholar
• Tsuji JS, Alexander DD, Perez V, et al. Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses. Toxicology. 2014;317:17–30.
   PubMed Web of Science ®Google Scholar
• Moon KA, Oberoi S, Barchowsky A, et al. A dose-response meta-analysis of chronic arsenic exposure and incident cardiovascular disease. Int J Epidemiol. 2017;46(6):1924–1939.
   PubMed Web of Science ®Google Scholar
• Jomova K, Jenisova Z, Feszterova M, et al. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011;31(2):95–107.
   PubMed Web of Science ®Google Scholar
• Yu S, Liao WT, Lee CH, et al. Immunological dysfunction in chronic arsenic exposure: from subclinical condition to skin cancer. J Dermatol. 2018;45(11):1271–1277.
   PubMed Web of Science ®Google Scholar
• Smith AH, Marshall G, Roh T, et al. Lung, bladder, and kidney cancer mortality 40 years after arsenic exposure reduction. J Natl Cancer Inst. 2018;110(3):241–249.
   PubMedGoogle Scholar
• Oberoi S, Devleesschauwer B, Gibb HJ, et al. Global burden of cancer and coronary heart disease resulting from dietary exposure to arsenic, 2015. Environ Res. 2019;171:185–192.
   PubMed Web of Science ®Google Scholar
• Khairul I, Wang QQ, Jiang YH, et al. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 2017;8(14):23905–23926.
   PubMedGoogle Scholar
• Naranmandura H, Suzuki N, Suzuki KT. Trivalent arsenicals are bound to proteins during reductive methylation. Chem Res Toxicol. 2006;19(8):1010–1018.
   PubMed Web of Science ®Google Scholar
• Rehman K, Fu YJ, Zhang YF, et al. Trivalent methylated arsenic metabolites induce apoptosis in human myeloid leukemic HL-60 cells through generation of reactive oxygen species [10.1039/C4MT00119B]. Metallomics. 2014;6(8):1502–1512.
   PubMed Web of Science ®Google Scholar
• Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003;63(8):1853–1859.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Moseley AB, Coutre SE, et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020;4(8):1683–1689.
   PubMed Web of Science ®Google Scholar
• Hernández-Zavala A, Matoušek T, Drobná Z, et al. Speciation analysis of arsenic in biological matrices by automated hydride generation-cryotrapping-atomic absorption spectrometry with multiple microflame quartz tube atomizer (multiatomizer). J Anal at Spectrom. 2008;23:342–351.
   PubMed Web of Science ®Google Scholar
• Matoušek T, Hernández-Zavala A, Svoboda M, et al. Oxidation state specific generation of arsines from methylated arsenicals based on L- Cysteine treatment in buffered media for speciation analysis by hydride Generation–Automated Cryotrapping–Gas Chromatography-Atomic absorption spectrometry with the multiatomizer. Spectrochim Acta Part B at Spectrosc. 2008;63(3):396–406.
   PubMed Web of Science ®Google Scholar
• Nigra AE, Sanchez TR, Nachman KE, et al. The effect of the environmental protection agency maximum contaminant level on arsenic exposure in the USA from 2003 to 2014: an analysis of the national health and nutrition examination survey (NHANES). Lancet Public Health. 2017;2(11):e513–e521.
   PubMed Web of Science ®Google Scholar
• Currier JM, Ishida MC, González-Horta C, et al. Associations between arsenic species in exfoliated urothelial cells and prevalence of diabetes among residents of Chihuahua, Mexico. Environ Health Perspect. 2014;122(10):1088–1094.
   PubMed Web of Science ®Google Scholar
• Mink PJ, Alexander DD, Barraj LM, et al. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Regul Toxicol Pharmacol. 2008;52(3):299–310.
   PubMed Web of Science ®Google Scholar
• Boffetta P, Borron C. Low-Level exposure to arsenic in drinking water and risk of lung and bladder cancer: a systematic review and dose-response meta-analysis. Dose Response. 2019;17(3):1559325819863634.
   Web of Science ®Google Scholar
• Naujokas MF, Anderson B, Ahsan H, et al. The broad scope of health effects from chronic arsenic exposure: update on a worldwide public health problem. Environ Health Perspect. 2013;121(3):295–302.
   PubMed Web of Science ®Google Scholar
• Cubadda F, Jackson BP, Cottingham KL, et al. Human exposure to dietary inorganic arsenic and other arsenic species: state of knowledge, gaps and uncertainties. Sci Total Environ. 2017;579:1228–1239.
   PubMed Web of Science ®Google Scholar
• Kuo CC, Moon KA, Wang SL, et al. The association of arsenic metabolism with cancer, cardiovascular disease, and diabetes: a systematic review of the epidemiological evidence. Environ Health Perspect. 2017;125(8):087001.
   PubMed Web of Science ®Google Scholar
• Vahter M, Concha G. Role of metabolism in arsenic toxicity. Pharmacol Toxicol. 2001;89(1):1–5.
   PubMedGoogle Scholar
• Zhou Q, Xi S. A review on arsenic carcinogenesis: epidemiology, metabolism, genotoxicity and epigenetic changes. Regul Toxicol Pharmacol. 2018;99:78–88.
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou J, Lu X, et al. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol. 2004;17(1):95–103.
   PubMed Web of Science ®Google Scholar
• Chen B, Cao F, Yuan C, et al. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Anal Bioanal Chem. 2013;405(6):1903–1911.
   PubMed Web of Science ®Google Scholar
• Kiguchi T, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Leuk Res. 2010;34(3):403–405.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang W, Hai X, et al. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells. J Pharm Biomed Anal. 2017;145:356–363.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Y, Meng H, et al. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Leuk Lymphoma. 2013;54(9):2041–2046.
   PubMed Web of Science ®Google Scholar
• Yoshino Y, Yuan B, Miyashita SI, et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem. 2009;393(2):689–697.
   PubMed Web of Science ®Google Scholar
• Iriyama N, Yoshino Y, Yuan B, et al. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. J Hematol Oncol. 2012;5:1.
   PubMed Web of Science ®Google Scholar
• Chen B, Cao F, Lu X, et al. Arsenic speciation in hair and nails of acute promyelocytic leukemia (APL) patients undergoing arsenic trioxide treatment. Talanta. 2018;184:446–451.
   PubMed Web of Science ®Google Scholar
• Koller BH, Snouwaert JN, Douillet C, et al. Arsenic metabolism in mice carrying a BORCS7/AS3MT locus humanized by syntenic replacement. Environ Health Perspect. 2020;128(8):87003.
   PubMed Web of Science ®Google Scholar
• Li J, Packianathan C, Rossman TG, et al. Nonsynonymous polymorphisms in the human AS3MT arsenic methylation gene: implications for arsenic toxicity. Chem Res Toxicol. 2017;30(7):1481–1491.
   PubMed Web of Science ®Google Scholar
• Lu J, Hu S, Wang W, et al. AS3MT polymorphisms, arsenic metabolism, and the hematological and biochemical values in APL patients treated with arsenic trioxide. Toxicol Sci. 2018;166(1):219–227.
   PubMed Web of Science ®Google Scholar
• Liu W-S, Wang X-Y, Lu J, et al. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. Arch Toxicol. 2020;94(4):1203–1213.
   PubMed Web of Science ®Google Scholar
• Lu J, Yu K, Fan S, et al. Influence of AS3MT polymorphisms on arsenic metabolism and liver injury in APL patients treated with arsenic trioxide. Toxicol Appl Pharmacol. 2019;379:114687.
   PubMed Web of Science ®Google Scholar
• Huffman DH, Benjamin RS, Bachur NR. Daunorubicin metabolism in acute nonlymphocytic leukemia. Clin Pharmacol Ther. 1972;13(6):895–905.
   PubMed Web of Science ®Google Scholar
• Wiley JS, Taupin J, Jamieson GP, et al. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest. 1985;75(2):632–642.
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2(7):685–698.
   PubMed Web of Science ®Google Scholar
• Drobná Z, Walton FS, Paul DS, et al. Metabolism of arsenic in human liver: the role of membrane transporters. Arch Toxicol. 2010;84(1):3–16.
   PubMed Web of Science ®Google Scholar